Precipio, Inc. (PRPO)
Nasdaq · Healthcare · Diagnostics & Research
$24.00+3.76%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $43.0M
- Forward P/E
- 61.5
- 52-week range
- $16.40 – $33.63
- 52-week change
- +14.45%
- EPS (trailing)
- −$0.65
Fiscal year to Dec 2025
- Revenue
- $24.0M (+29.77%)
- Net income
- −$363K
- Operating margin
- −5.0%
- Diluted EPS
- −$0.23
- Free cash flow
- $360K
From the company’s annual report on SEC EDGAR.
About Precipio, Inc.
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
Headquarters: New Haven, United States · 61 employees · precipiodx.com